Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2022

View Archived Issues

Oncostatin M blockade ameliorates severe asthma

Targeting DICAM impedes migration of disease-inducing leukocytes into the CNS in multiple sclerosis

Nanodecoys scavenge RANKL and TNF-alpha for osteoporosis treatment

Kallyope presents new AMPK activators

Jiangsu Hengrui Medicine and Shanghai Hengrui Pharmaceutical patent new ATR kinase inhibitors

Sun Pharmaceutical Industries divulges GIPR and GLP-1 receptor dual agonists

Medshine Discovery synthesizes new JAK3 inhibitors

Red Bull GmbH presents dopamine reuptake inhibitors

DNA-PK activates survival kinase AKT in response to DNA damage

Targeting specific behavioral immune traits of inflammation

BATF promotes lung tissue protection during acute respiratory virus infection

Targeting PARP could fight cancer-associated virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...